KRAS AMPLIFICATION Detail (hg19) (KRAS)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr12:25,362,365-25,403,737 |
| hg38 | chr12:25,209,431-25,250,803 View the variant detail on this assembly version. |
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| skin melanoma | Carboplatin,Sorafenib,Docetaxel | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 26307133 | Detail |
| endometrial cancer | B |
Prognostic
|
Supports
|
Poor Outcome | Somatic | 3 | 23099803 | Detail | |
| melanoma | Vemurafenib | D |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 24265155 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with car... | CIViC Evidence | Detail |
| In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3... | CIViC Evidence | Detail |
| In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- KRAS
- Genome
- hg19
- Position
- chr12:25,362,365-25,403,737
- Variant Type
- cnv
- Variant (CIViC) (CIViC Variant)
- AMPLIFICATION
- Transcript 1 (CIViC Variant)
- ENST00000256078.4
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/592
Genome browser